Research Papers: Pathology:

Interleukin-13 peptide vaccine induces protective humoral immunity in murine asthma models

Fengbo Wu, Yan Huang, Peng Zhang, Chunting Wang, Yaomei Tian, Lian Lu, Gu He and Li Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:6678-6690. https://doi.org/10.18632/oncotarget.19950

Metrics: PDF 1434 views  |   HTML 3114 views  |   ?  


Fengbo Wu1, Yan Huang1, Peng Zhang2, Chunting Wang1, Yaomei Tian1, Lian Lu1, Gu He1 and Li Yang1

1 Department of Pharmacy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, P.R. China

2 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China

Correspondence to:

Li Yang, email:

Gu He, email:

Keywords: interleukin-13, asthma, synthetic peptide, vaccine, Pathology Section

Received: June 09, 2017 Accepted: July 25, 2017 Published: August 04, 2017


This study presents a rational design approach to discovery synthetic peptide vaccine candidates from endogenous proteins for chronic non-infectious diseases immunological therapeutics. The approach described the screening of key antigenic amino acid residues of the interleukine-13, which is up-regulated expression in asthma, followed by the development of immunological helper epitope peptides via an integrative computational and experimental method. Notably, this totally synthetic peptide vaccine was capable of stimulating humoral immune responses much stronger than those of parental antigenic peptides by enhancing the efficiency of antigen presentation, and had effective treatment in mouse asthma models. Our approach offers new possibilities to discovery therapeutic peptide vaccine candidates for chronic non-infectious diseases, with highly consolidated in silico and animal disease models for fast iterative screening.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19950